Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2024-01-12 Transaction in Own Shar…
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Simcere Pharmaceutical Group Limited. It details multiple repurchases of shares over various dates, including quantities and prices, and confirms compliance with listing rules. The content is focused on reporting share repurchase transactions and changes in issued share capital, not on financial results, management changes, or other report types. This matches the description of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares. The document is substantive and detailed, not a brief announcement or certification, so it is not Regulatory Filings or Report Publication Announcement. Therefore, the correct classification is POS (Transaction in Own Shares).
2024-01-12 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Simcere Pharmaceutical Group Limited. It details multiple repurchases of shares over various dates, including quantities and prices, and confirms compliance with listing rules. The content is focused on reporting share repurchase transactions and changes in issued share capital, not on financial results, management commentary, or other report types. This matches the description of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares. The document is substantive and detailed, not a brief announcement or certification, so it is not Regulatory Filings or Report Publication Announcement. Therefore, the correct classification is POS (Transaction in Own Shares).
2024-01-08 English
VOLUNTARY ANNOUNCEMENT - THE PHASE III CLINICAL STUDY OF SUVEMCITUG FOR INJECTION IN THE TREATMENT OF PLATINUM-RESISTANT OVARIAN CANCER HAS SUCCESSFULLY MET THE PRIMARY STUDY ENDPOINT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding the successful primary endpoint achievement of a Phase III clinical study for a drug (Suvemcitug) in treating platinum-resistant ovarian cancer. It provides detailed clinical trial results, study background, and future plans for drug application submission. There are no financial statements, regulatory certifications, or references to annual or quarterly reports. The content focuses on business development and clinical trial progress rather than financial performance or governance. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial results and business updates that do not fit into other specific categories like financial reports, management changes, or capital updates.
2024-01-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
Regulatory Filings Classification · 100% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 December 2023. It details movements in issued shares, share options, warrants, convertibles, and other share-related activities for Simcere Pharmaceutical Group Limited. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited (HKEX) and focuses on share capital movements and confirmations. It does not contain financial statements, management discussion, or earnings data. The document is a regulatory filing related to share capital movements and compliance with listing rules, not a financial report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS).
2024-01-03 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Simcere Pharmaceutical Group Limited. It details repurchases of shares on various dates, quantities, and prices, confirming compliance with listing rules. The content is a regulatory disclosure about share repurchases and capital changes, not a financial report or earnings release. It fits the category of a report on the company's transactions in its own shares (share buybacks). Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length and detail confirm it is not a brief announcement but a formal disclosure report.
2024-01-02 English
CONNECTED TRANSACTION IN RELATION TO THE ACQUISITION OF ENTIRE EQUITY INTEREST IN THE TARGET COMPANY
M&A Activity Classification · 95% confidence The document is an announcement by Simcere Pharmaceutical Group Limited regarding a connected transaction involving the acquisition of the entire equity interest in a target company. It details the terms of the acquisition, valuation methodology, payment arrangements, completion conditions, and general information about the parties involved. The content focuses on a corporate transaction rather than financial results, management changes, or regulatory filings. The document is lengthy (15,000 characters) and contains substantive details about the acquisition, which aligns with announcements related to mergers and acquisitions activity. There is no indication that this is a full merger proxy statement or tender offer filing, but rather an announcement of an acquisition transaction. Therefore, the most appropriate classification is M&A Activity (Code: TAR).
2024-01-01 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.